TLR7 and Erythema: Reported side effects are usually mild and include pain, irritation, erythema, erosion and residual hypopigmentation.8, 17, 24, 25, 26, 27, 28 Imiquimod is an immunomodulatory agent targeting the toll-like-receptor 7 as a receptor agonist and it has direct antitumor activity.7, 17, 25 In 2014, a retrospective study by Luyten et al27 involving 21 cases treated with imiquimod reported a 52.4% complete response rate, a 28.6% partial response rate, and no documented cases of disease progression.